Coronado Biosciences, Inc. announced that effective January 28, 2014, Dr. Kevin Horgan, Chief Medical Officer, was separated from service from company. On February 20, 2014, Board named current director, Mr. Michael S. Weiss, Executive Vice Chairman, Strategic Development. Mr. Weiss has served as a director of company since December 19, 2013 and from that time until February 19, 2014 served as the Co-Vice Chairman of Board.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.84 USD | +0.55% | -1.60% | -38.87% |
May. 15 | Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 15 | Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q1 Revenue $13M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.87% | 36.65M | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- FBIO Stock
- News Fortress Biotech, Inc.
- Coronado Biosciences, Inc. Appoints Michael S. Weiss as Executive Vice Chairman, Strategic Development